Federal judge stops compounded copies of Eli Lilly weight loss, diabetes drugs
A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro.
In a sealed decision filed late Wednesday, Judge Mark Pittman of the Northern District of Texas declined to issue an injunction to stop the Food and Drug Administration (FDA) from declaring there was no longer a shortage of the medicines' active ingredient, tirzepatide.
The lawsuit against FDA was brought in October by a trade organization representing compounding industry groups. The Outsourcing Facilities Association (OFA) alleged the agency was “abruptly depriving patients of much needed treatment and artificially raising drug prices.”
Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs, so long as the FDA considered them in shortage.
Compounded drugs are sold at vastly lower prices than the branded versions, but drug companies and some obesity specialists have expressed concerns that some compounded products aren’t FDA-approved.
After the suit was filed, the FDA temporarily paused to reconsider the declaration to end the shortage but ultimately reaffirmed its decision in December. The agency said it would not take any enforcement action against compounders before the court ruled.
The agency at the time gave drug compounders a transition period to avoid patient care disruption. Smaller state-licensed pharmacies had until Feb. 18 and now must immediately stop producing their own copies of the drugs.
Larger outsourcing facilities, which are FDA-regulated and can create prescription-specific compounded drugs as well as bulk orders, must cease compounding, distributing or dispensing tirzepatide injections by March 19.
OFA’s lawsuit said FDA made its decision to remove tirzepatide from the shortage list based only on statements from the manufacturer, “without notice, without soliciting input from affected parties and the public, and without meaningful rationale.”
In a statement to The Hill on Thursday, OFA Chair Lee Rosebush said the group “is considering all of its options regarding the judgment, including an appeal.”
Rosebush said he couldn’t comment on specifics of the decision until the court unseals it.
Eli Lilly in a statement said the decision “marks the end of the road for mass compounding of risky, unapproved knockoffs that threaten the health and safety of Americans.”
Any company that continues mass compounding tirzepatide “is breaking the law, and we will work with regulators and law enforcement to stop it,” a company spokesperson said.
A similar OFA lawsuit against FDA for removing semaglutide, the active ingredient in Ozempic, from the shortage list is pending.
-
From pills to new uses, here's what Eli Lilly’s top scientist sees as the future of weight loss drugs
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.CNBC - Feb. 20 -
Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower doses in vials in August.CNBC - Feb. 25 -
Eli Lilly cuts price of weight-loss drug Zepbound as competition heats up
The drug company is calling on insurers and federal programs to cover obesity as a chronic disease.MarketWatch - Feb. 26 -
Drug compounders sue over weight loss drugs' removal from FDA shortage list
A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for removing semaglutide, the active ingredient in Ozempic, from its drug ...The Hill - Feb. 25 -
Hims & Hers shares tumble after company misses on margin, says may stop selling some weight loss drugs
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended trading.CNBC - Feb. 24 -
Novo’s Weight Loss Drugs Removed from FDA Shortage List
The FDA said weight-loss and diabetes drugs Wegovy and Ozempic are no longer on shortage list.Inc. - Feb. 22 -
Healthy Returns: AbbVie is the newest potential weight loss drug market player
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS conference gets underway in Vegas.CNBC - 2d -
Why Walmart’s warning may have more to do with weight-loss drugs than tariffs
Walmart’s stock fell Thursday as quarterly earnings were expected to decline for the first time in three years, with strength in groceries and GLP-1 drug sales continuing to pressure margins.MarketWatch - Feb. 21 -
We know so little about taking weight-loss drugs without prescription – is it really worth it? | Devi Sridhar
Studies show that they’re effective for overweight people, but if you’re healthy, there are less risky ways to lose weight. When I’ve been in the gym over the past few months, one of the things ...The Guardian - Feb. 25
More from The Hill
-
Murphy fears more Medicare pay cuts will kill private practice
Rep. Greg Murphy (R-N.C.) worries that if nothing is done to curb Medicare payment cuts to physicians, doctors will no longer be able to afford to run their own private practices. “We’re at a ...The Hill - 26m -
Canadian senator challenges Donald Trump Jr. to charity boxing match over 'bogus tariffs'
Canadian Sen. Patrick Brazeau challenged Donald Trump Jr. to a charity boxing match over the “bogus” tariffs implemented this week by his father, President Trump. "I know, I still can't believe it ...The Hill - 44m -
Trump reverses with tariff exemptions
Welcome to The Hill's Business & Economy newsletter {beacon} Business & Economy Business & Economy The Big Story Trump reverses on Canada, Mexico tariffs with exemptions President Trump, in his ...The Hill - 1h -
Ontario will tariff electricity going to 3 US states on Monday, premier says
Ontario Premier Doug Ford said three states would face tariffs on electricity after a week of President Trump’s swipes at Canada with fluctuating trade policies. “I love Americans. It's been 20 ...The Hill - 1h -
New Zealand fires top diplomat in London over Trump remarks
New Zealand's top diplomat in the United Kingdom was fired after making comments about President Trump in London earlier this week. New Zealand's high commissioner to the U.K., Phil Goff, was ...The Hill - 1h
More in Politics
-
Murphy fears more Medicare pay cuts will kill private practice
Rep. Greg Murphy (R-N.C.) worries that if nothing is done to curb Medicare payment cuts to physicians, doctors will no longer be able to afford to run their own private practices. “We’re at a ...The Hill - 26m -
Canadian senator challenges Donald Trump Jr. to charity boxing match over 'bogus tariffs'
Canadian Sen. Patrick Brazeau challenged Donald Trump Jr. to a charity boxing match over the “bogus” tariffs implemented this week by his father, President Trump. "I know, I still can't believe it ...The Hill - 44m -
Trump reverses with tariff exemptions
Welcome to The Hill's Business & Economy newsletter {beacon} Business & Economy Business & Economy The Big Story Trump reverses on Canada, Mexico tariffs with exemptions President Trump, in his ...The Hill - 1h -
Ontario will tariff electricity going to 3 US states on Monday, premier says
Ontario Premier Doug Ford said three states would face tariffs on electricity after a week of President Trump’s swipes at Canada with fluctuating trade policies. “I love Americans. It's been 20 ...The Hill - 1h -
New Zealand fires top diplomat in London over Trump remarks
New Zealand's top diplomat in the United Kingdom was fired after making comments about President Trump in London earlier this week. New Zealand's high commissioner to the U.K., Phil Goff, was ...The Hill - 1h